Company Announcements:
(reported by the Company)
No items found
Elevator Pitch:

Acuvax Ltd (ASX: ACU) is in the process of acquiring Biolife Science Ltd, which is developing a vaccine for breast and gastric cancers. On 22 March 2013, Acuvax shareholders voted overwhlemingly to approve the acquisition of Biolife and to raise $5m to fund Phase 2 trials of the vaccine.

Category: Health & biotech
Operational Status: Active
ASX Listing Code (if applicable): ACU
Year of Commencement: 2001

Suite 4, 16 Ord Street, WEST PERTH, WA, AUSTRALIA, 6005

State: Western Australia
Overseas Operations: No
Key Personnel:
Validated Problem Solver Engagements:
No items found
Awards won:
Current Period Rank:

WA Annual Rank 2016: 463



Company News:

NOTE: Company News, Milestones and Funding are as collected by Techboard as part of our Monthly Startup Ranking

Amount Seeking:
Type of capital raise:
Pre-money valuation:
ESIC Status:
ESIC Upload:
Future Intentions:
Investment Video:
Investment Pitchdeck:
Investment URL:
Investment Phone:
Investment Email:

Leave a Reply